FindTrial
Sign In

High-dose methylprednisolone

DRUG4 trials

Sponsors

Dana-Farber Cancer Institute, Kite, A Gilead Company, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Zou Junjie

Conditions

Acute Liver FailureAcute Liver InjuryCLLFulminant Hepatic FailureGraves OphthalmopathyHepatic EncephalopathyHigh Grade B-cell Lymphoma (HGBCL)Immune Dysregulation

Phase 1

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma
CompletedNCT02348216
Kite, A Gilead CompanyHigh Grade B-cell Lymphoma (HGBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), Refractory Diffuse Large B Cell Lymphoma (DLBCL) +2
Start: 2015-04-21End: 2023-07-27Updated: 2024-06-04

Phase 2

Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL
TerminatedNCT01465334
Dana-Farber Cancer InstituteCLL, SLL
Start: 2011-12-31End: 2017-01-31Updated: 2023-08-29
TReatment for ImmUne Mediated PathopHysiology
RecruitingNCT04862221
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Acute Liver Failure, Acute Liver Injury, Fulminant Hepatic Failure +2
Start: 2022-02-09End: 2027-02-01Target: 163Updated: 2026-03-10

Unknown Phase

Multi-center Prospective Clinical Study on Glucocorticoid Pulse Therapy for Graves' Ophthalmopathy (GO)
Enrolling by invitationNCT06693856
Zou JunjieGraves Ophthalmopathy
Start: 2025-01-01End: 2026-12-31Target: 120Updated: 2025-05-22

Related Papers

Indirect Comparison of Epcoritamab Versus Axicabtagene Ciloleucel in Chimeric Antigen Receptor T-Cell-Eligible and -Naive Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
2025-07-31
Durable response to CAR T is associated with elevated activation and clonotypic expansion of the cytotoxic native T cell repertoire
Nature Communications2025-05-235 citations
Efficacy of Axicabtagene Ciloleucel Compared to Historical Treatments for Relapsed/Refractory Diffuse Large B-Cell Lymphoma of Asian Descent: A Matching Adjusted Indirect Comparison of ZUMA-1 vs REAL-TREND.
2025-05-01
Hypomagnesemia in lymphoma patients receiving CAR T therapy correlates with immune dysfunction and decreased survival
Experimental Hematology and Oncology2025-04-30
Abstract 867: Multi-omic characterization of tumor microenvironment evolution in LBCL across treatment lines: Insights from Atlas classification and axicabtagene ciloleucel trials
Cancer Research2025-04-21
Investigating the Influence of Covariates on Axicabtagene Ciloleucel (axi-cel) Kinetics in Patients with Non-Hodgkin's Lymphoma.
2024-09-061 citations
Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity
Blood2024-04-1821 citations
Abstract LB346: Dynamic changes in the tumor microenvironment from initial diagnosis through sequential therapies in patients with large B cell lymphoma undergoing axicabtagene ciloleucel (axi-cel) treatment
Cancer Research2024-04-051 citations
Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7
Blood Advances2024-02-0510 citations
Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma
Nature Medicine2024-01-1794 citations
Impact of debulking therapy on the clinical outcomes of axicabtagene ciloleucel in the treatment of relapsed or refractory large B-cell lymphoma
American Journal of Cancer Research2024-01-012 citations
An Inflammatory Biomarker Signature Reproducibly Predicts CAR-T Treatment Failure in Patients with Aggressive Lymphoma across the Zuma Trials Cohorts
Blood2023-11-024 citations
Poor Hematopoietic Reserve at the Time of CD19 CAR T-Cell Infusion Is Associated with Long Term B-Cell Aplasia
Blood2023-11-023 citations
Pre- and Post-Treatment Immune Contexture Correlates with Long Term Response in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel (axi-cel)
Blood2023-11-021 citations
Efficacy of Subcutaneous Epcoritamab Vs Tisa-Cel in R/R LBCL CAR T-Naive and CAR T-Eligible Patients: An Indirect Comparison
Blood2023-11-021 citations
CAR-T Therapy in Patients With High-Risk Large B-Cell Lymphoma
Oncology Times2023-08-07
A phase 2 trial of defibrotide for the prevention of chimeric antigen receptor T-cell–associated neurotoxicity syndrome
Blood Advances2023-07-0318 citations
5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)
Blood2023-02-23212 citations
Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma
Blood2022-07-1568 citations
P1744: ACCURACY OF PREDICTING LONG-TERM SURVIVAL OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPIES IN LARGE B-CELL LYMPHOMA (LBCL)
HemaSphere2022-06-01

48 more papers not shown